newsfilter
← Latest News
GlobeNewswire·

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that HLS Therapeutics Inc. (TSX:HLS), the Company's partner in Canada for the development and commercialization of